ArticleBlood2011
IRF4 mutations in chronic lymphocytic leukemia.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- The dynamic functions of IRF4 in B cell malignancies.Clinical and experimental medicine · 2023Review
- The molecular basis for the development of adult T-cell leukemia/lymphoma in patients with an IRF4Protein science : a publication of the Protein Society · 2022Article
- IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.Leukemia · 2021Article
- Structural determinants of the IRF4/DNA homodimeric complex.Nucleic acids research · 2021Article
- Genome-Wide Association Analyses Identify Variants inFrontiers in genetics · 2021Article
- Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci.Human molecular genetics · 2020Article
- Beyond the coding genome: non-coding mutations and cancer.Frontiers in bioscience (Landmark edition) · 2020Review
- Genomic basis for RNA alterations in cancer.Nature · 2020Article
- An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.The Journal of biological chemistry · 2018Article
- Review
- IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.PLoS pathogens · 2017Article
- LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required.Oncogene · 2017Article
- Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.Experimental hematology · 2017Article
- Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.Oncotarget · 2016Article
- IRF4 and IRF8 Act in CD11c+ Cells To Regulate Terminal Differentiation of Lung Tissue Dendritic Cells.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.Blood · 2014Article
- IRF4 and IRF8: Governing the virtues of B Lymphocytes.Frontiers in biology · 2014Article
- Article
- Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?Immunology · 2014Review
- Interferons and their stimulated genes in the tumor microenvironment.Seminars in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory factor family of transcription factors and has been shown to have critical functions at several stages of B-cell development. Genome-wide association study identified a polymorphism in the 3' untranslated region of IRF4 as a chronic lymphocytic leukemia risk locus. In this study, we report a recurrent heterozygous somatic mutation in the DNA-binding domain of IRF4 detected in 7 of 457 chronic lymphocytic leukemia patients (1.5%). Patients with IRF4 mutation have a good prognosis, and 4 of 6 have a trisomy 12. We also found that IRF4 mRNA expression is higher in the patients with the mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.